Abstract Number: 2663 • 2018 ACR/ARHP Annual Meeting
Comparison of Clinical and Laboratory Profiles in 3575 Systemic Lupus Erythematosus Patients with and without Sjögren’s Syndrome: Data from the Spanish Society for Rheumatology Lupus Registry
Background/Purpose: The clinical coexistence of Systemic Lupus Erythematosus (SLE) and Sjögren's Syndrome (SS) was recognized in 1959. The prevalence of SS among patients with SLE…Abstract Number: 2664 • 2018 ACR/ARHP Annual Meeting
Long-Term Clinical Outcomes in a Cohort of Adults with Childhood-Onset Systemic Lupus Erythematosus
Background/Purpose: Childhood-onset SLE (cSLE) is a severe lifelong multisystem autoimmune disease. Long-term outcome data are limited. Here, we report for the first time on the…Abstract Number: 2665 • 2018 ACR/ARHP Annual Meeting
Treatment Trends of Systemic Lupus Erythematosus during Early-Years of the Disease
Background/Purpose: Systemic lupus erythematosus (SLE) is treated with glucocorticoids, anti-malarials, immunosuppressive medications, and, more recently, biologics (specifically, belimumab and rituximab). While belimumab had positive results…Abstract Number: 2666 • 2018 ACR/ARHP Annual Meeting
Trends in Treatment of Systemic Lupus Erythematosus and Lupus Nephritis: 2006-2016
Background/Purpose: Glucocorticoids, anti-malarials and conventional immunosuppressive agents have been the mainstay of therapy for systemic lupus erythematosus (SLE) and lupus nephritis (LN); more recently biologic…Abstract Number: 2667 • 2018 ACR/ARHP Annual Meeting
Sledai and Mex-Sledai Glucocorticoid Indices As Predictors of Damage and Mortality in Multinational Multiethnic Latin American Cohort
Background/Purpose: Disease activity is one of the major predictors of damage accrual and mortality in systemic lupus erythematosus (SLE). Glucocorticoid use, especially in high dose,…Abstract Number: 2668 • 2018 ACR/ARHP Annual Meeting
Hydroxychloroquine and the Risk of Thrombotic Events in Systemic Lupus Erythematosus Patients : A Systematic Review and Meta-Analysis
Hydroxychloroquine and Risk of Thrombosis in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-analysisAuthors : Sankhyan P, Boonpheng B, Cook CT Background/Purpose: Over…Abstract Number: 2669 • 2018 ACR/ARHP Annual Meeting
Assessing the Need for Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis in SLE Patients on Immunosuppression
Background/Purpose: The risk-benefit of Pneumocystis jiroveci pneumonia (PCP) prophylaxis in systemic lupus erythematosus (SLE) is not well defined and there are no SLE-specific guidelines. On…Abstract Number: 2670 • 2018 ACR/ARHP Annual Meeting
Association of Hydroxychloroquine Use and Incident Atrial Fibrillation in Systemic Lupus Erythematosus: A Retrospective Study
Background/Purpose: Hydroxychloroquine (HCQ) is a derivative of quinidine, a class 1a anti-arrhythmic agent used to prevent ventricular arrhythmias and recurrent atrial fibrillation (AFib). AFib occurs…Abstract Number: 2671 • 2018 ACR/ARHP Annual Meeting
Development and First-in-Human Characterization of an ICOSL and BAFF Bispecific Inhibitor AMG 570 for SLE Treatment
Background/Purpose: Autoimmune diseases, including systemic lupus erythematosus (SLE), are associated with dysregulated T cell and B cell responses. AMG 570 is a bispecific molecule targeting…Abstract Number: 2672 • 2018 ACR/ARHP Annual Meeting
Serum Vitamin D Levels and Its Effect on Disease Activity and Fatigue in Systemic Lupus Erythematosus Patients
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease involving many organs and systems. Evidences show that vitamin D plays an important role…Abstract Number: 2673 • 2018 ACR/ARHP Annual Meeting
Different Risk Profiles for Development of Steroid-Related and Steroid-Unrelated Damage in Early Diagnosed SLE: Results from the Italian Multicenter Early Lupus Project Inception Cohort
Background/Purpose:Preventing organ damage is a major challenge in Systemic Lupus Erythematosus (SLE).To evaluate factors associated with development of steroid-related and unrelated damage in an inception…Abstract Number: 2674 • 2018 ACR/ARHP Annual Meeting
Identifying Phenotype Clusters in Systemic Lupus Erythematosus By Damage Cluster
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a multisystem autoimmune disease with complex genetic background. Recently, subphenotype in SLE has influenced dialogue on discussing the genetic…Abstract Number: 2675 • 2018 ACR/ARHP Annual Meeting
Age-Related Metabolic Changes Underlie Pro-Inflammatory Lineage Specification and Contribute to Therapeutic Responsiveness to Mechanistic Target of Rapamycin Blockade in SLE
Background/Purpose: Systemic lupus erythematosus (SLE) patients exhibit T-cell dysfunction which can be reversed by blockade of the mechanistic target of rapamycin (mTOR) with therapeutic efficacy…Abstract Number: 2676 • 2018 ACR/ARHP Annual Meeting
SLE Patients with No Organ Damage Might Benefit More from Belimumab Treatment
Background/Purpose: In systemic lupus erythematosus (SLE), organ damage is associated with unfavourable disease courses and premature mortality. We aimed at investigating the impact of organ…Abstract Number: 2677 • 2018 ACR/ARHP Annual Meeting
A Systematic Review Examining the Association between Organ Damage and Health-Related Quality of Life in Systemic Lupus Erythematosus
Background/Purpose: SLE-related organ damage is associated with increased morbidity. The comorbidity burden of SLE can involve various organ systems and may include pain, fatigue, difficulty…
ACR Meeting Abstracts